Clinical evaluations
EPIT safety evaluation considered both local and systemic adverse reactions reported weekly by owners. Primary and secondary efficacy outcomes were established. Figure 2 represents the evaluation timeline.
Primary outcomes:
Secondary outcomes:
Owner-reported QoL survey46.
Allergen-specific IgE serology (LETIPharma S.L.U.).